DK3436463T3 - Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat - Google Patents

Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat Download PDF

Info

Publication number
DK3436463T3
DK3436463T3 DK17719053.5T DK17719053T DK3436463T3 DK 3436463 T3 DK3436463 T3 DK 3436463T3 DK 17719053 T DK17719053 T DK 17719053T DK 3436463 T3 DK3436463 T3 DK 3436463T3
Authority
DK
Denmark
Prior art keywords
thieno
hemi
azabicyclo
pyrazol
pyrimidin
Prior art date
Application number
DK17719053.5T
Other languages
English (en)
Inventor
Kentaro Iwata
Masahiro Mizuno
Kazuhiro Maeda
Tsuneo Yasuma
Misaki Homma
Yuya Oguro
Naohiro Taya
Lei Zhu
John Daniel Bailey
Siddhesh Dinanath Patil
Shruti Gour
Lilly Roy
Marianne Langston
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of DK3436463T3 publication Critical patent/DK3436463T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
DK17719053.5T 2016-03-28 2017-03-27 Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat DK3436463T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314080P 2016-03-28 2016-03-28
US201662367842P 2016-07-28 2016-07-28
PCT/US2017/024226 WO2017172565A1 (en) 2016-03-28 2017-03-27 Crystalline forms of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h- pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one hemihydrate

Publications (1)

Publication Number Publication Date
DK3436463T3 true DK3436463T3 (da) 2021-08-30

Family

ID=58609973

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17719053.5T DK3436463T3 (da) 2016-03-28 2017-03-27 Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat

Country Status (11)

Country Link
US (1) US11746109B2 (da)
EP (1) EP3436463B1 (da)
JP (2) JP6918824B2 (da)
CN (1) CN108779126B (da)
CA (1) CA3016708A1 (da)
DK (1) DK3436463T3 (da)
ES (1) ES2884398T3 (da)
PL (1) PL3436463T3 (da)
PT (1) PT3436463T (da)
TW (1) TWI738748B (da)
WO (1) WO2017172565A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
DK3436463T3 (da) * 2016-03-28 2021-08-30 Takeda Pharmaceuticals Co Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat
CN112409373A (zh) * 2017-05-21 2021-02-26 南京正济医药研究有限公司 作为抗癌剂的取代的[5,6]环-4(3h)-嘧啶酮
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3774816A1 (en) * 2018-04-02 2021-02-17 Takeda Pharmaceutical Company Limited Process for the synthesis of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6- (3-methyl-1 h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one
CN112513296A (zh) * 2018-06-19 2021-03-16 武田药品工业株式会社 基于tp53突变状态和超突变状态的癌症治疗方法
KR20210033483A (ko) * 2018-07-19 2021-03-26 다케다 야쿠힌 고교 가부시키가이샤 Cdc7 억제제를 갖는 약제학적 조성물
BR112021023886A2 (pt) * 2019-05-30 2022-01-18 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compostos tetracíclicos como inibidores de cdc7
US20220267341A1 (en) * 2019-06-24 2022-08-25 Naurex Inc. Solid forms of tert-butyl (s)-2((2s,3r)-1-amino-3-hydroxy-1-oxobu tan-2-yl)-1-oxo-2, 5-diazaspiro [3.4] octan e-5-carboxylate and methods of preparing them
CA3146792A1 (en) 2019-07-19 2021-01-28 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment
EP4253388A1 (en) * 2020-11-30 2023-10-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Salt form used as cdc7 inhibitor and crystal form thereof
US20240173323A1 (en) 2021-02-08 2024-05-30 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011216404B2 (en) * 2010-02-17 2016-04-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
DK3436463T3 (da) * 2016-03-28 2021-08-30 Takeda Pharmaceuticals Co Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat

Also Published As

Publication number Publication date
JP2020143076A (ja) 2020-09-10
CN108779126B (zh) 2021-07-16
TWI738748B (zh) 2021-09-11
TW201736383A (zh) 2017-10-16
JP6918824B2 (ja) 2021-08-11
CA3016708A1 (en) 2017-10-05
WO2017172565A1 (en) 2017-10-05
CN108779126A (zh) 2018-11-09
JP2019510033A (ja) 2019-04-11
EP3436463B1 (en) 2021-06-23
PL3436463T3 (pl) 2021-11-08
PT3436463T (pt) 2021-09-06
EP3436463A1 (en) 2019-02-06
US20230102273A1 (en) 2023-03-30
ES2884398T3 (es) 2021-12-10
US11746109B2 (en) 2023-09-05

Similar Documents

Publication Publication Date Title
DK3436463T3 (da) Krystalline former af 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-on hemi-hydrat
IL266897B (en) History of thiano[2,3–d]pyrimidines for the treatment of viral infections
FR22C1006I2 (fr) Derives de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des janus kinases (jak)
HK1245764A1 (zh) 3-取代的5-氨基-6h-噻唑並[4，5-d]嘧啶-2，7-二酮化合物
PL3345907T3 (pl) Związki pirazolo[3,4-d]pirymidynowe lub ich sole
MA46054A (fr) Procédé de préparation de pyrazolo[1,5-a]pyrimidines et de sels de celles-ci
DK3555097T3 (da) Imidazo[4,5-d]pyrrolo[2,3-b]pyridinforbindelser som inhibitorer af janus-kinaser
EP3435320A4 (en) INTERNET SYSTEM OF INTELLIGENT DOMESTIC ENERGY OBJECTS FOR INTELLIGENT CITY SYSTEM
MA52906A (fr) Procédé de préparation d'amg 416
DK3287460T3 (da) Hemisulfatsalt af 5,10-methylen-(6r)-tetrahydrofolsyre
DK3400225T3 (da) Pentansyrederivater substitueret med pyrrolo-[2,3-b]pyrimidinpyridiner til behandling af influenzavirusinfektioner
IL255901B (en) Crystal of (6s,9as)–n–benzyl–8–({6–[3–(4–ethylpiperazin–1–yl)azetidin–1–yl]pyridin–2–yl}methyl)–6–(2– fluoro-4-hyfroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h )-carboxamide
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
DK3397621T3 (da) Fremgangsmåde til fremstilling af 1,1,3-trioxo-1,2-benzothiazol-6-carboxamid
DK3459953T3 (da) Hidtil ukendt 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-on-derivat
DK3362453T3 (da) Cykliske etherderivater af pyrazolo[1,5-a]pyrimidin-3-carboxyamid
FR3022234B1 (fr) Procede de preparation de nanofils de silicium.
FR3048968B1 (fr) Procede de preparation d'alkylamines
DK3397620T3 (da) Fremgangsmåde til fremstilling af 1,1,3-Trioxo-1,2-benzothiazol-6-carboxamid
FR3049599B1 (fr) Procede de preparation de l'hexafluorobutadiene.
DK3194408T3 (da) Tetrahydropyrrolo[3,4-d][1,3]thiazin-derivat som bace-inhibitor
FR3035265B1 (fr) Procede de fabrication de transistors soi pour une densite d'integration accrue
TH1601000114A (th) อนุพันธ์ไทอีโน [3,2-d] ไพริมิดีน สำหรับการบำบัดการติดเชื้อไวรัส
FR3050860B3 (fr) Flute optimisee pour l'apprentissage facilite par les enfants